{"commentary":{"count":14,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":8,"youtube":5,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04154956\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CARMEN-LC03","nct_id":"NCT04154956","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=carmen-lc03-nct04154956. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"CARMEN-LC03","arms":[{"description":"Participants received tusamitamab ravtansine 100 milligrams per square meter (mg/m\\^2) by intravenous (IV) infusion, once every 2 weeks (Q2W) until objective progressive disease (PD), unacceptable adverse event/toxicity, upon participant's request to stop treatment, or Investigator decision, whichever occurred first (maximum exposure: 147 weeks).","label":"SAR408701 (tusamitamab ravtansine)","type":"EXPERIMENTAL"},{"description":"Participants received docetaxel 75 mg/m\\^2 by IV infusion, once every 3 weeks (Q3W) until objective PD, unacceptable adverse event/toxicity, upon participant's request to stop treatment, or Investigator decision, whichever occurred first (maximum exposure: 115 weeks).","label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-04-16","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer Metastatic"],"enrollment":{"count":389,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"SAR408701","type":"DRUG"},{"name":"Docetaxel","type":"DRUG"}],"last_update":"2026-05-18","lead_sponsor":"Sanofi","official_title":"Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-09-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Tumor assessments performed at screening, and every 8 weeks +/-5 days thereafter, up to 189 weeks"},{"measure":"Overall Survival (OS)","timeFrame":"From date of first study treatment administration (Day 1) until the date of death due to any cause, up to 189 weeks"}],"references":[],"start_date":{"date":"2020-02-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","url":"https://clinicaltrials.gov/study/NCT04154956"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/carmen-lc03-nct04154956"}